Web Exclusives

Web Exclusives | May 15, 2018
These results make quizartinib the first FLT3 inhibitor to demonstrate such improvement over chemotherapy in this patient population.

Subscribe to the Journal of Oncology Navigation & Survivorship®

To sign up for our print publication or e-newsletter, please enter your contact information below.

  • First Name *
    Last Name *
     
    Country
  • Please enter your mailing address.

    Address
     
    Address Line 2
    City
     
    State
    Zip Code